Catalogue No.
16022509
MCF7/TAMR-7
MCF7/TAMR-7
Cell Line Name
MCF7/TAMR-7
Cell Line Description
The MCF7/TAMR-7 Cell line is a breast cancer cell line resistant to tamoxifen. Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-7 cell line is a good model cell to study the signalling pathways, which are the major drivers of tamoxifen-resistant growth.The parental cell line for the MCF7/TAMR-7 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-7 has been established from a clone of cells that survived long term treatment with 1 µM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 µM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line
General Info
Species
Human
Links
Cellosaurus: CVCL_1D43
Release Conditions
Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.
Characteristics
Tissue of Origin
Breast
Morphology
Polygonal
DNA profile (STR Profile)
Amelogenin: X
CSF1PO: 10
D3S1358: 16
D5S818: 11,12
D7S820: 8,9
D8S1179: 10,14
D13S317: 11
D16S539: 11,12
D18S51: 14
D21S11: 30
FGA: 23,25
Penta D: 12
Penta E: 7,12
TH01: 6
TPOX: 9,12
vWA: 14,15
CSF1PO: 10
D3S1358: 16
D5S818: 11,12
D7S820: 8,9
D8S1179: 10,14
D13S317: 11
D16S539: 11,12
D18S51: 14
D21S11: 30
FGA: 23,25
Penta D: 12
Penta E: 7,12
TH01: 6
TPOX: 9,12
vWA: 14,15
Applications
The MCF7/TAMR-7 cell line is a good model to study the signalling pathways which are the major drivers of tamoxifen-resistant growth.MCF7/TAMR-7 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-7 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-7 cell.The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen started in passage 351. Few colonies of cells survived the treatment; after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells
Disease
Carcinoma
Culture Conditions
Cell Type
Epithelial
Subculture Routine
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C. Recommend media changes every 2-3 days
Culture Medium
37°C under 5% CO₂ in air using phenol red-free DMEM:Ham's F-12 containing 1% foetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 µM).
Growth Mode
Adherent
Additional Info
Depositor
Cancer Research Technologies Limited (Ximbio)
Country of Origin
Denmark
Hazard Group (ACDP)
Hazard Group (ACDP) 2
Applications
References
Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755
Bibliography
Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577. Pedersen et al. 2014. Int J Oncol. 45(5):2167-75. PMID: 25175082. Lundqvist et al. 2014. Steroids. 85:30-5. PMID: 24747771. Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470. Larsen et al. 2012. Int J Oncol. 41(5):1863-70. PMID: 22961366. Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041. Berstein et al. 2003. Endocr Relat Cancer. 10(2):267-77. PMID: 12790788.
Available Formats
- Frozen
Citation Guidance
If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/TAMR-7 (ECACC 16022509).
Biosafety Information
Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Further Information
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.